HIV vaccine development in the aftermath of the STEP study: Re-focus on occult hiv infection?

PLoS Pathogens

Volumn 4, Issue 8, 2008, Pages

  Überla, Klaus ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GAG PROTEIN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEF PROTEIN; PLACEBO; POL PROTEIN; VIRUS ANTIBODY; VIRUS PROTEIN;

ADAPTIVE IMMUNITY; CELL ACTIVATION; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG DELIVERY SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; INCIDENCE; INFECTION PREVENTION; LAMINA PROPRIA; NONHUMAN; NOTE; POST HOC ANALYSIS; STRUCTURAL GENE; VACCINATION; VIRAL GENE DELIVERY SYSTEM; VIRUS ENVELOPE; VIRUS LOAD; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS TRANSMISSION; ADENOVIRUS; ANIMAL; BYSTANDER EFFECT; IMMUNOLOGY; PHASE 1 CLINICAL TRIAL; PRIMATE; REVIEW;

ADENOVIRIDAE; AIDS VACCINES; ANIMALS; ANTIBODIES, VIRAL; BYSTANDER EFFECT; CLINICAL TRIALS, PHASE I AS TOPIC; HIV INFECTIONS; HUMANS; PRIMATES; T-LYMPHOCYTES, CYTOTOXIC; VIRAL PROTEINS;

EID: 50849126803     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1000114     Document Type: Note

References (11)

1. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF (2005) Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 191: 654-665.
2. Karlsson Hedestam GB, Fouchier RA, Phogat S, Burton DR, Sodroski J, Wyatt RT (2008) The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 6: 143-155.
3. Robertson M, Casimiro DR, De Rosa S, Dubey S, Kierstead L, McElrath J (2008) Immunological Characterization of Subjects from the STEP Study: A Phase IIB Test-of-Concept Trial of the MRKAd5 HIV-1 Gag/Pol/Nef Trivalent Vaccine.
4. Robertson M, Mehrotra D, Fitzgerald D, Duerr A, Casimiro DR, McElrath J , Lawrence D, Buchbinder S (2008) Efficacy Results from the STEP Study (Merck V520 Protocol 023/HVTN 502): A Phase II Test-of-Concept Trial of the MRKAd5 HIV-1 Gag/Pol/Nef Trivalent Vaccine.
5. Buchbinder S (2008) STEP Trial: Exploring hypotheses for differential HIV acquisition rates. HVTN Full Group Meeting November 7, 2007.
6. McElrath J, Casimiro DR (2008) The STEP Trial. A Pathway Toward Understanding the Biological Basis for the Vaccine Efficacy Results. HVTN Full Group Meeting November 7, 2007.
7. Rowland-Jones SL, McMichael A (1995) Immune responses in HIV-exposed seronegatives: have they repelled the virus? Curr Opin Immunol 7: 448-455.
8. Kulkarni PS, Butera ST, Duerr AC (2003) Resistance to HIV-1 infection: lessons learned from studies of highly exposed persistently seronegative (HEPS) individuals. AIDS Rev 5: 87-103.
9. McChesney MB, Collins JR, Lu D, Lu X, Torten J, Ashley RL, Cloyd MW, Miller CJ (1998) Occult systemic infection and persistent simian immunodeficiency virus (SIV)-specific CD4(+)-T-cell proliferative responses in rhesus macaques that were transiently viremic after intravaginal inoculation of SIV. J Virol 72: 10029-10035.
10. Tasca S, Tsai L, Trunova N, Gettie A, Saifuddin M, Bohm R, Chakrabarti L, Cheng-Mayer C (2007) Induction of potent local cellular immunity with low dose X4 SHIV(SF33A) vaginal exposure. Virology 367: 196-211.
11. Haase AT (2005) Perils at mucosal front lines for HIV and SIV and their hosts. Nat Rev Immunol 5: 783-792.